Gene Therapy for Auditory Synaptopathy: Current Evidence and Clinical Perspectives

Abstract

Auditory synaptopathy represents a unique subset of sensorineural hearing loss characterized by disrupted transmission at the synapse between inner hair cells and auditory nerve fibers. Traditional interventions have shown limited efficacy, prompting exploration of gene therapy as a targeted solution. This review synthesizes recent advances in gene therapy for auditory synaptopathy, emphasizing mechanistic insights, clinical implications, and future research directions. Evidence from experimental models and early-phase clinical studies underpins the promise of gene-based approaches to restore synaptic function and improve auditory outcomes.

Introduction

Auditory synaptopathy is a complex auditory disorder that impairs the synaptic communication between inner hair cells (IHCs) and spiral ganglion neurons (SGNs), resulting in significant challenges for affected individuals. Unlike conventional cochlear pathologies, auditory synaptopathy often preserves outer hair cell function, leading to distinct clinical presentations. As conventional hearing aids and cochlear implants may not fully address synaptic deficits, gene therapy has emerged as a compelling avenue for targeted intervention. This article provides a comprehensive review of the epidemiology, pathophysiology, clinical features, diagnostic strategies, and emerging gene therapy approaches for auditory synaptopathy, catering to the educational needs of clinicians and researchers.

Epidemiology / Disease Burden

The true prevalence of auditory synaptopathy remains underrecognized due to diagnostic challenges and overlap with other forms of hearing loss. Epidemiological studies estimate that auditory synaptopathy accounts for 10-15% of permanent sensorineural hearing loss in children and adults. It is particularly common among neonates with risk factors such as prematurity, hyperbilirubinemia, and genetic predispositions. The disease burden is significant, as patients often experience disproportionate difficulty with speech discrimination, especially in noisy environments, leading to impaired communication, developmental delays in children, and reduced quality of life. Growing awareness and improved diagnostic capabilities are refining prevalence estimates and guiding resource allocation for research and therapy development.

Pathophysiology

Auditory synaptopathy is characterized by dysfunction at the ribbon synapses of IHCs, which are essential for rapid and precise neurotransmission to SGNs. Genetic mutations affecting key synaptic proteins, such as otoferlin (OTOF), have been implicated. Otoferlin deficiency disrupts synaptic vesicle exocytosis, leading to impaired auditory signaling despite intact cochlear amplification. Other implicated mechanisms include postsynaptic receptor dysfunction, glutamate excitotoxicity, and synaptic degeneration due to noise exposure or ototoxic insults. Animal models have elucidated the molecular pathways underlying synaptic maintenance and repair, laying the foundation for targeted gene therapy strategies.

Risk Factors

Risk factors for auditory synaptopathy are heterogeneous and include both genetic and environmental contributors. Inherited mutations in genes such as OTOF, PJVK, and DIAPH3 are established causes, particularly in autosomal recessive forms. Acquired risk factors encompass perinatal hypoxia, neonatal jaundice with kernicterus, exposure to aminoglycoside antibiotics, and chronic noise exposure. Age-related synaptopathy, or "hidden hearing loss", is increasingly recognized in older adults with noise exposure histories. Understanding risk profiles is essential for timely diagnosis and consideration of advanced therapies, including gene-based interventions.

Clinical Features

Patients with auditory synaptopathy typically demonstrate normal otoacoustic emissions (OAEs), reflecting preserved outer hair cell function, yet present with abnormal or absent auditory brainstem responses (ABRs). This dissociation is a diagnostic hallmark. Clinically, affected individuals may report fluctuating hearing thresholds, difficulty understanding speech in noisy settings, and poor temporal resolution. In pediatric populations, these deficits manifest as speech and language delays, academic challenges, and social withdrawal. The spectrum of severity ranges from mild communication difficulties to profound auditory disability.

Diagnosis

Diagnosis relies on a combination of audiological and electrophysiological assessments. Key diagnostic tests include pure-tone audiometry, OAEs, and ABRs. The presence of robust OAEs with abnormal ABRs strongly suggests auditory synaptopathy. Additional tests, such as cochlear microphonics and electrocochleography, may further differentiate synaptopathies from other auditory neuropathies. In cases with suspected genetic etiology, molecular genetic testing for mutations in OTOF and related genes is recommended. Early and accurate diagnosis is critical for guiding management and considering eligibility for emerging gene therapies.

Treatment & Management

Conventional management options, such as hearing aids and cochlear implants, offer variable benefit in auditory synaptopathy due to the underlying synaptic deficit. Hearing aids may improve audibility but often fail to address speech discrimination challenges. Cochlear implants can bypass dysfunctional synapses and directly stimulate SGNs, providing meaningful auditory input in some cases, particularly when postsynaptic structures are preserved. However, outcomes are inconsistent, and some patients derive limited benefit. Auditory training and speech therapy play complementary roles in maximizing functional outcomes. The limitations of current therapies underscore the need for mechanism-based interventions such as gene therapy.

Recent Advances / Emerging Therapies

Gene therapy has emerged as a transformative approach for hereditary auditory synaptopathy, particularly in cases of OTOF-related deafness. Preclinical studies using adeno-associated viral (AAV) vectors to deliver functional OTOF cDNA into IHCs have demonstrated restoration of synaptic transmission and auditory function in murine models. Several research groups have optimized AAV serotypes and delivery techniques to enhance transduction efficiency and minimize immunogenicity. Early-phase clinical trials are underway, exploring the safety and efficacy of intracochlear gene therapy for pediatric patients with OTOF mutations. Additional strategies, such as genome editing (CRISPR/Cas9) and RNA-based therapies, are being investigated for their potential to correct or modulate defective synaptic genes. Despite promising preclinical results, challenges remain regarding vector delivery, long-term expression, immune response, and scalability to human cochlear anatomy.

Guideline Recommendations

Current clinical guidelines emphasize the importance of early detection and comprehensive diagnostic workup for suspected auditory synaptopathy. Genetic counseling and molecular testing are recommended for families with hereditary forms. While gene therapy remains investigational, referral to specialized centers for clinical trial enrollment should be considered for eligible patients. Multidisciplinary management, including audiology, otology, genetics, and speech-language pathology, is essential for optimizing outcomes. As gene therapy advances toward clinical application, professional societies are expected to issue updated recommendations regarding patient selection, safety monitoring, and long-term follow-up.

Conclusion

Auditory synaptopathy represents a diagnostically and therapeutically challenging disorder with significant impact on communication and quality of life. Advances in molecular genetics and synaptic biology have paved the way for innovative gene therapy approaches targeting the root causes of synaptic dysfunction. Preclinical and early clinical data suggest that gene therapy holds promise for restoring auditory function in select patient populations, particularly those with monogenic etiologies such as OTOF mutations. Ongoing research will determine the long-term safety, efficacy, and broader applicability of these therapies. Multidisciplinary care and adherence to evolving guidelines remain paramount as the field transitions from experimental models to clinical reality.